Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Frede Donskov, Robert J. Motzer, Eric Voog, Elizabeth J. Hovey, Carsten Grüllich, Louise M. Nott, Katharine Ellen Cuff, Thierry Gil, Niels Viggo Jensen, Christine Chevreau, Sylvie Negrier, Reinhard Depenbusch, Lothar Bergmann, Izzy Cornelio, Anne Champsaur, Bernard J. Escudier, Sumanta K. Pal, Thomas Powles, Toni K. Choueiri
Institutions: Aarhus University Hospital, Memorial Sloan Kettering Cancer Center, Centre Jean Bernard, Prince of Wales Hospital, National Center for Tumor Diseases, Royal Hobart Hospital, Princess Alexandra Hospital, Institut Jules Bordet, Odense University Hospital, Institut Claudius Regaud, Centre Léon Bérard, University Hospital Frankfurt, Exelixis (United States), Institut Gustave Roussy, City Of Hope National Medical Center, Barts Cancer Institute, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4234519912